vTv Therapeutics Q3 net loss $8.7M; Phase 3 CATT1 data expected H2 2026

vTv Therapeutics Inc.

Net loss $8.7M ($1.08 per share) vs $4.8M loss ($0.88) in Q3 2024.
Cash $98.5M at Sept 30, 2025, up from $36.7M at Dec 31, 2024, after $80M private placement.
First patient randomized in Phase 3 CATT1 trial of cadisegliatin; topline data H2 2026.
U.S. patent allowed for crystalline salt forms of cadisegliatin; exclusivity through 2041.
R&D expenses $7.0M, more than double Q3 2024, due to cadisegliatin spend and milestone accrual.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.